Catalyst Wire Dossier Catalyst Wire Dossier

Autologous tumor-infiltrating lymphocyte (TIL) therapy

tumor infiltrating lymphocytes (TIL) therapy
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Autologous tumor-infiltrating lymphocyte (TIL) therapy, covering 2024-09-19 to 2025-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors [NA]

See pricing